Jason Nathaniel Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jason Nathaniel Johnson has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
- Shyam Sathanandam
Le Bonheur Children's Hospital, United States
8 shared publications - Ranjit Philip
Department of Pediatric Cardiology, Le Bonheur Children’s Hospital, Memphis, TN 38103, USA
7 shared publications - Anthony Merlocco
Division of Pediatric Cardiology The University of Tennessee Health Science Center Memphis Tennessee USA
6 shared publications - Cara E. Morin
Cincinnati Children’s Hospital Medical Center, Cincinnati, United States
5 shared publications - Jeffrey A. Towbin
Department of Pediatrics, University of Tennessee Health Science Center, Le Bonheur Children’s Hospital, Memphis (J.A.T.).
5 shared publications - Benjamin Rush Waller
Le Bonheur Children's Hospital, United States
4 shared publications
Latest Publications
- 18 October 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2244-2251
Sustained improvement in sickle cell cardiomyopathy after haematopoietic stem cell transplantation is superior to that with disease‐modifying therapy
Summary: Allogeneic haematopoietic stem cell transplantation (HSCT) is curative for sickle cell disease (SCD) ‐ a group of inherited haemoglobin disorders encompassing homozygous haemoglobin S (HbSS) and compound heterozygous sickling disorders, including haemoglobin SC disease (HbSC), haemoglobin S/β 0 ‐thalassaemia (HbSβ 0 ), haemoglobin S/β + ‐thalassaemia (HbSβ + ), etc., but its long‐term impact on SCD myocardial remodelling is incompletely characterized. We performed serial cardiac magnetic resonance imaging (CMR) and echocardiography in children and young adults with SCD undergoing matched‐sibling or haploidentical HSCT in a prospective clinical trial with up to 36 months of post‐HSCT follow‐up. CMR assessments were conducted before HSCT and through the post‐HSCT period. Echocardiographic parameters at 12 months post HSCT were compared with those of age‐matched participants receiving disease‐modifying therapies (DMTs). Among 20 HSCT recipients (mean age 14.8 years), CMR demonstrated progressive reductions in biventricular volumes and left atrial volume over 36 months, with preservation of ejection fraction. Extra‐cellular volume, a surrogate marker of myocardial fibrosis, showed significant improvement from baseline, having normalized in nearly all participants assessed at 36 months. Compared with age‐matched DMT recipients, HSCT recipients had lower tricuspid regurgitant jet velocity and improved diastolic parameters at 12 months post‐HSCT, with normalization of cardiac output on echocardiography. These findings demonstrate sustained reversal of myocardial fibrosis and structural cardiac remodelling after HSCT for SCD. HSCT may, therefore, modify the trajectory of SCD cardiomyopathy beyond the improvements achieved with current DMTs.
- 18 October 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2244-2251
Sustained improvement in sickle cell cardiomyopathy after haematopoietic stem cell transplantation is superior to that with disease‐modifying therapy
Summary: Allogeneic haematopoietic stem cell transplantation (HSCT) is curative for sickle cell disease (SCD) ‐ a group of inherited haemoglobin disorders encompassing homozygous haemoglobin S (HbSS) and compound heterozygous sickling disorders, including haemoglobin SC disease (HbSC), haemoglobin S/β 0 ‐thalassaemia (HbSβ 0 ), haemoglobin S/β + ‐thalassaemia (HbSβ + ), etc., but its long‐term impact on SCD myocardial remodelling is incompletely characterized. We performed serial cardiac magnetic resonance imaging (CMR) and echocardiography in children and young adults with SCD undergoing matched‐sibling or haploidentical HSCT in a prospective clinical trial with up to 36 months of post‐HSCT follow‐up. CMR assessments were conducted before HSCT and through the post‐HSCT period. Echocardiographic parameters at 12 months post HSCT were compared with those of age‐matched participants receiving disease‐modifying therapies (DMTs). Among 20 HSCT recipients (mean age 14.8 years), CMR demonstrated progressive reductions in biventricular volumes and left atrial volume over 36 months, with preservation of ejection fraction. Extra‐cellular volume, a surrogate marker of myocardial fibrosis, showed significant improvement from baseline, having normalized in nearly all participants assessed at 36 months. Compared with age‐matched DMT recipients, HSCT recipients had lower tricuspid regurgitant jet velocity and improved diastolic parameters at 12 months post‐HSCT, with normalization of cardiac output on echocardiography. These findings demonstrate sustained reversal of myocardial fibrosis and structural cardiac remodelling after HSCT for SCD. HSCT may, therefore, modify the trajectory of SCD cardiomyopathy beyond the improvements achieved with current DMTs.
- Open Access
- 20 January 2026
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 28 (1) , 102695
Society for Cardiovascular Magnetic Resonance 2024 Cases of SCMR case series
- 20 January 2026
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 28 (1) , 102695
Open AccessSociety for Cardiovascular Magnetic Resonance 2024 Cases of SCMR case series
- 19 June 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- p. e011531
Eosinophilic Myocarditis in Children From Toxocara Canis: A Case and Review of the Literature
- 19 June 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- p. e011531
Eosinophilic Myocarditis in Children From Toxocara Canis: A Case and Review of the Literature
- Open Access
- 9 June 2025
- Published by Springer Nature in Pediatric Radiology
- Vol. 55 (11) , 2381-2399
Cardiac magnetic resonance imaging in the assessment of cardiac injury and toxicity from cancer-related chemotherapy
A dedicated guideline to the evaluation of cardiovascular toxicity in pediatric cancer by cardiac magnetic resonance imaging (MRI) does not exist. Therefore, the aim of this document is to provide guidance in the utility, acquisition, and interpretation of cardiac MRI in childhood cancer survivors. We will focus on briefly defining cardiovascular toxicity in childhood cancer survivors and reviewing the key aspects of a detailed cardiac MRI study in a patient with acute versus chronic cardiovascular toxicity. We intend for this document to serve as a guideline on how to perform a cardiac MRI to evaluate cardiac toxicity based on a review of the current literature. There will be a review of a detailed cardiac MRI protocol (bi-ventricular volumes and mass, myocardial strain, tissue characterization, late gadolinium enhancement, and 4 Dimensional/4D flow) in the assessment of cardiovascular toxicity from cancer therapy. It is hoped that the availability of a standardized approach to cardiac MRI assessment in childhood cancer survivors improves cardiovascular care in this population. Graphical Abstract
- 9 June 2025
- Published by Springer Nature in Pediatric Radiology
- Vol. 55 (11) , 2381-2399
Open AccessCardiac magnetic resonance imaging in the assessment of cardiac injury and toxicity from cancer-related chemotherapy
A dedicated guideline to the evaluation of cardiovascular toxicity in pediatric cancer by cardiac magnetic resonance imaging (MRI) does not exist. Therefore, the aim of this document is to provide guidance in the utility, acquisition, and interpretation of cardiac MRI in childhood cancer survivors. We will focus on briefly defining cardiovascular toxicity in childhood cancer survivors and reviewing the key aspects of a detailed cardiac MRI study in a patient with acute versus chronic cardiovascular toxicity. We intend for this document to serve as a guideline on how to perform a cardiac MRI to evaluate cardiac toxicity based on a review of the current literature. There will be a review of a detailed cardiac MRI protocol (bi-ventricular volumes and mass, myocardial strain, tissue characterization, late gadolinium enhancement, and 4 Dimensional/4D flow) in the assessment of cardiovascular toxicity from cancer therapy. It is hoped that the availability of a standardized approach to cardiac MRI assessment in childhood cancer survivors improves cardiovascular care in this population. Graphical Abstract
- Open Access
- 12 September 2024
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 26 (2) , 101091
Practice patterns of cardiovascular magnetic resonance use in the diagnosis of pediatric myocarditis: A survey-based study
- 12 September 2024
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 26 (2) , 101091
Open AccessPractice patterns of cardiovascular magnetic resonance use in the diagnosis of pediatric myocarditis: A survey-based study
- 8 August 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (6) , 672-675
Impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease
Serial cardiovascular magnetic resonance evaluation of children and young adults with SCD who underwent hematopoietic cell transplantation showed mean ECV, representing diffuse myocardial fibrosis, decreased 3.4% from baseline to 12 months posttransplantation. This trial was registered at www.clinicaltrials.gov as #NCT04362293.
- 8 August 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (6) , 672-675
Impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease
Serial cardiovascular magnetic resonance evaluation of children and young adults with SCD who underwent hematopoietic cell transplantation showed mean ECV, representing diffuse myocardial fibrosis, decreased 3.4% from baseline to 12 months posttransplantation. This trial was registered at www.clinicaltrials.gov as #NCT04362293.
- Open Access
- 9 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (8) , 2168
Lessons from the Pandemic: Role of Percutaneous ECMO and Balloon Atrial Septostomy in Multi-System Inflammatory Syndrome in Children
Multi-system inflammatory syndrome in children (MIS-C) in the setting of COVID-19 can be associated with severe cardiopulmonary dysfunction. This clinical deterioration may sometimes necessitate veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. We describe an algorithmic approach including the role of balloon atrial septostomy in this cohort. This is the first reported series of percutaneous VA-ECMO in pediatric patients with MIS-C for better outcomes. The lessons from this approach can be replicated in other pediatric clinical conditions and adds to the armament of multiple pediatric specialties.
- 9 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (8) , 2168
Open AccessLessons from the Pandemic: Role of Percutaneous ECMO and Balloon Atrial Septostomy in Multi-System Inflammatory Syndrome in Children
Multi-system inflammatory syndrome in children (MIS-C) in the setting of COVID-19 can be associated with severe cardiopulmonary dysfunction. This clinical deterioration may sometimes necessitate veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. We describe an algorithmic approach including the role of balloon atrial septostomy in this cohort. This is the first reported series of percutaneous VA-ECMO in pediatric patients with MIS-C for better outcomes. The lessons from this approach can be replicated in other pediatric clinical conditions and adds to the armament of multiple pediatric specialties.
- Open Access
- 23 March 2024
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 26 (1) , 101041
Design and implementation of multicenter pediatric and congenital studies with cardiovascular magnetic resonance: Big data in smaller bodies
- 23 March 2024
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 26 (1) , 101041
Open AccessDesign and implementation of multicenter pediatric and congenital studies with cardiovascular magnetic resonance: Big data in smaller bodies
- 8 November 2023
- Published by American College of Radiology
CPI Obstetric & Gynecologic Imaging Special Edition Module
- 8 November 2023
- Published by American College of Radiology
CPI Obstetric & Gynecologic Imaging Special Edition Module
- Open Access
- 18 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (3) , 100663
O-4 | Low Risk of Thyroid Dysfunction in Children <3 Years After Exposure to Iodine-Containing Contrast Agents in Cardiac Catheterization
- 18 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (3) , 100663
Open AccessO-4 | Low Risk of Thyroid Dysfunction in Children <3 Years After Exposure to Iodine-Containing Contrast Agents in Cardiac Catheterization